Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Mar 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with HPV-related oropharynx cancer, which is a type of throat cancer linked to the human papillomavirus. The trial aims to see if combining targeted radiation therapy with two immune-boosting drugs, Evorpacept and Pembrolizumab, before surgery can improve how well patients respond to treatment. The hope is that this method will not only help shrink tumors but also strengthen the body's immune response against the cancer.

To be eligible for this trial, participants must be adults aged 65 to 74, have a confirmed diagnosis of early-stage HPV oropharynx cancer, and be able to undergo surgery safely. They should also be able to receive the radiation and drugs involved in the study. Patients with certain types of lymph node involvement may not qualify. Those who participate can expect to receive the combination treatment before their scheduled surgery, with ongoing monitoring to assess the effectiveness of this approach. This trial is currently recruiting participants, and it represents an opportunity to explore a potentially more effective treatment for this type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed diagnosis of Stage I T1-2N1M0 HPVOPC (Human Papilloma Virus Oropharynx Cancer)
• • Amenable to surgical resection
• • Are able to safely receive neoadjuvant radiation and Evorpacept/Pembrolizumab
• Exclusion Criteria:
• • • Patients with solitary lymph nodes less than 3 cm